Clinical trials for irritable bowel syndrome treatments should be designed to demonstrate not just short-term benefit but also efficacy in maintenance and retreatment, FDA said in a recently finalized guidance on IBS drug development.
The recommendation for evaluation of longer-term effects marks a change from a 2010 draft guidance, which focused on efficacy over a two- to
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?